Barbara C Tilley1, Nancy R LaPelle2, Christopher G Goetz3, Glenn T Stebbins3. 1. Division of Biostatistics, University of Texas School of Public Health at Houston, Houston, TX, USA. 2. Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA. 3. Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
Abstract
BACKGROUND: Cognitive pretesting, a qualitative step in scale development, precedes field testing and assesses the difficulty of instrument completion for examiners and respondents. Cognitive pretesting assesses respondent interest, attention span, discomfort, and comprehension, and highlights problems with the logical structure of questions/response options that can affect understanding. In the past this approach was not consistently used in the development or revision of movement disorders scales. METHODS: We applied qualitative cognitive pretesting using testing guides in development of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The guides were based on qualitative techniques, verbal probing and "think-aloud" interviewing, to identify problems with the scale from the patient and rater perspectives. English-speaking Parkinson's disease patients and movement disorders specialists (raters) from multiple specialty clinics in the United States, Western Europe and Canada used the MDS-UPDRS and completed the testing guides. RESULTS: Two rounds of cognitive pretesting were necessary before proceeding to field testing of the revised scale to assess clinimetric properties. Scale revisions based on cognitive pretesting included changes in phrasing, simplification of some questions, and addition of a reassuring statement explaining that not all PD patients experience the symptoms described in the questions. CONCLUSIONS: The strategy of incorporating cognitive pretesting into scale development and revision provides a model for other movement disorders scales. Cognitive pretesting is being used in translating the MDS-UPDRS into multiple languages to improve comprehension and acceptance and in the development of a new Unified Dyskinesia Rating Scale for Parkinson's disease patients.
BACKGROUND: Cognitive pretesting, a qualitative step in scale development, precedes field testing and assesses the difficulty of instrument completion for examiners and respondents. Cognitive pretesting assesses respondent interest, attention span, discomfort, and comprehension, and highlights problems with the logical structure of questions/response options that can affect understanding. In the past this approach was not consistently used in the development or revision of movement disorders scales. METHODS: We applied qualitative cognitive pretesting using testing guides in development of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The guides were based on qualitative techniques, verbal probing and "think-aloud" interviewing, to identify problems with the scale from the patient and rater perspectives. English-speaking Parkinson's diseasepatients and movement disorders specialists (raters) from multiple specialty clinics in the United States, Western Europe and Canada used the MDS-UPDRS and completed the testing guides. RESULTS: Two rounds of cognitive pretesting were necessary before proceeding to field testing of the revised scale to assess clinimetric properties. Scale revisions based on cognitive pretesting included changes in phrasing, simplification of some questions, and addition of a reassuring statement explaining that not all PDpatients experience the symptoms described in the questions. CONCLUSIONS: The strategy of incorporating cognitive pretesting into scale development and revision provides a model for other movement disorders scales. Cognitive pretesting is being used in translating the MDS-UPDRS into multiple languages to improve comprehension and acceptance and in the development of a new Unified Dyskinesia Rating Scale for Parkinson's diseasepatients.
Authors: Christopher Christodoulou; Doerte U Junghaenel; Darren A DeWalt; Nan Rothrock; Arthur A Stone Journal: Qual Life Res Date: 2008-10-12 Impact factor: 4.147
Authors: Holly John; Gareth J Treharne; Elizabeth D Hale; Vasileios F Panoulas; Douglas Carroll; George D Kitas Journal: Patient Educ Couns Date: 2009-04-22
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Christopher G Goetz; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Glenn T Stebbins; Matthew B Stern; Barbara C Tilley; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J Van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2007-01 Impact factor: 10.338
Authors: Rwei-Ling Yu; Ruey-Meei Wu; Anne Y Y Chan; Vincent Mok; Yih-Ru Wu; Barbara C Tilley; Sheng Luo; Lu Wang; Nancy R LaPelle; Glenn T Stebbins; Christopher G Goetz Journal: Mov Disord Clin Pract Date: 2016-04-08
Authors: Jesse M Cedarbaum; Diane Stephenson; Richard Rudick; Maria C Carrillo; Glenn Stebbins; Douglas Kerr; Jill Heemskerk; Wendy R Galpern; Petra Kaufmann; David Cella; Maria Isaac; Marc K Walton Journal: Neurotherapeutics Date: 2015-01 Impact factor: 7.620
Authors: Pablo Martinez-Martin; Anette Schrag; Daniel Weintraub; Alexandra Rizos; Carmen Rodriguez-Blazquez; Kallol Ray Chaudhuri Journal: Mov Disord Clin Pract Date: 2019-02-05
Authors: Anika Frank; Jonas Bendig; Sophia Finkbeiner; Tom Hähnel; Nils Schnalke; Tim Feige; Heinz Reichmann; Björn H Falkenburger Journal: Mov Disord Clin Pract Date: 2022-07-23
Authors: Logan R Thornton; Rossybelle P Amorrortu; Daniel W Smith; Arch G Mainous; Sally W Vernon; Barbara C Tilley Journal: Contemp Clin Trials Commun Date: 2016-06-24
Authors: Jinse Park; Seong Beom Koh; Kyum Yil Kwon; Sang Jin Kim; Jae Woo Kim; Joong Seok Kim; Kun Woo Park; Jong Sam Paik; Young H Sohn; Jin Young Ahn; Eungseok Oh; Jinyoung Youn; Ji Young Lee; Phil Hyu Lee; Wooyoung Jang; Han Joon Kim; Beom Seok Jeon; Sun Ju Chung; Jin Whan Cho; Sang Myung Cheon; Suk Yun Kang; Mee Young Park; Seongho Park; Young Eun Huh; Seok Jae Kang; Hee Tae Kim Journal: J Clin Neurol Date: 2020-10 Impact factor: 3.077